Navigation Links
Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Date:1/7/2008

rietary protein that inactivates the action of Rho, a key enzyme that prevents axon regeneration and recovery after SCI. It has been granted Orphan Drug Status in the U.S. In February 2005, enrollment began in an open-label, non-placebo-controlled, dose-escalating Phase I/IIa trial in subjects with acute SCI at sites in the United States and Canada. The trial assessed 5 dose levels of Cethrin from 0.3 mg to 9 mg in both thoracic and cervical injuries.

The trial design includes a number of post-treatment evaluations of the subjects for safety and efficacy for up to one year after treatment. The efficacy measurements assess changes in subjects' sensory and motor functions, as well as overall recovery as measured by the American Spinal Injury Association, or ASIA, Impairment Scale. The ASIA Impairment Scale is used to score subjects within five categories from A to E, with A being complete impairment with no sensory or motor function below the site of injury and E being normal. Grades B through E designate increasing levels of motor and sensory function. The subjects in the Cethrin Phase I/IIa trial suffered a complete thoracic or cervical SCI and were thus classified as an A on the ASIA Impairment Scale at the time of enrollment in the trial.

The 6-month interim data on 37 of these subjects treated with doses of up to 6 mg indicate that 27% of the Cethrin treated subjects improved from ASIA A to ASIA B or better. This is more than 400% greater than the conversion rate seen with the standard of care in a similarly designed study reported by Burns and colleagues in the Journal of Neurotrauma. When subjects with cervical injuries who were treated with Cethrin were analyzed separately, about 46% of the subjects exhibited a conversion rate from ASIA A to ASIA B or better. Moreover, about 18% of subjects overall and 38% of subjects with cervical injuries improved to ASIA C or better over the six months the hallmark of which is recovery of some motor function.
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
2. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
3. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... , Aug. 3, 2015  Isis Pharmaceuticals, ... announced a strategic collaboration to discover and develop ... The new collaboration builds on a broad existing ... strategic approach in these therapeutic areas using novel ... extend use of its antisense technology to diseases ...
(Date:8/2/2015)... Mandatory takeover offer for ... or the "Company") is pleased to announce the signing ... Marijan Han žeković to acquire his 63.3% holding ... a Croatian listed pharmaceutical business.   Dechra ... to €51.4 million for the entire share capital on ...
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
Breaking Medicine Technology:AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 2AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 3AstraZeneca and Isis Pharmaceuticals to Discover and Develop Antisense Drugs for Cardiovascular, Metabolic and Renal Diseases 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
(Date:8/1/2015)... , ... August 01, 2015 , ... Have you ever wondered what “Karma” really means? ... hear the word “Karma.” , Vedic tradition, which gave birth to Hinduism, is one ... of the central concepts of this tradition. According to the wisdom of this heritage, Karma ...
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of ... Wilcoxson was given that honor by the National Retail Federation, the largest retail trade ... was one of three Maine business owners to be named as such. According to ...
(Date:8/1/2015)... ... , ... On Tuesday, July 28th, Symantec released a security industry whitepaper ... the attack on Anthem Inc. which resulted in one of the largest data breaches ... spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO of ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers allows users to clarify, edit and delete any message including ones already ...
(Date:7/31/2015)... ... ... is a reputable source of authentic tickets for the 2015 iHeart Radio Music Festival ... of music will have an act they are excited to see at this two-day festival. ... will perform: Sam Smith, Coldplay, Kenny Chesney, The Who, Jason Derulo, Demi Lovato, Duran ...
Breaking Medicine News(10 mins):Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Local Retail Advocate Wins National Recognition 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3
... Now that ... medical billing video explains how in easy to understand terms. , ... Washington, DC (Vocus) December 15, 2009 -- On January ... to Medicare for reimbursement when a patient is seen for a medical consultation, whether in ...
... "We ... a part of. We know by bringing Dr. Foshee into the Dermatology Center of Dallas, ... ... Dermatology Center of Dallas, a Dallas based, full-service medical and cosmetic dermatology practice, proudly announces ...
... ... gather, need to have an automated external defibrillator (AED) readily available. Fire and rescue ... investment. , ... December 15, 2009 -- Starting January 1, 2010 Oregon will require that certain businesses with ...
... , SAN DIEGO, Dec. 15 "The entire San Diego ... passing of Sol Price on December 14, 2009. Mr. Price ... and ethics in his business, community and personal life. Mr. ... the responsibility of philanthropy and the role it plays in ...
... 15, 2009 UT Southwestern Medical Center researchers have ... unique observable characteristics seen in patients with an extremely ... and in the December issue of the Journal ... with atypical progeroid syndrome (APS) should not be lumped ...
... ... ... at UC Santa Barbara, in collaboration with scientists at University of Michigan, have developed ... cells, including softness, flexibility, and the ability to carry oxygen. , , , ...
Cached Medicine News:Health News:Medicare Eliminates Consultation Codes for Doctors 2Health News:Jeri Beth “J.B.” Foshee, MD Joins Dermatology Center of Dallas 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2Health News:Researchers ID traits of people with rare accelerated aging syndrome 2Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3
... Strep A Test is a color immunochromatographic ... uses antibody labeled color particles coated at ... DLT allows greater sensitivity than the conventional ... the test procedure, a throat swab is ...
... The IntraLase FS laser introduces new high ... Surgeons now have the opportunity to offer ... to a microkeratome for creating the corneal ... FS laser and proprietary IntraLASIK software, surgeons ...
... Teco Diagnostics manufactures fine urine ... our urine chemistry reagent strips from ... to offer more economical prices compared ... the quality. Teco Diagnostics urine reagent ...
... term complications associated with diabetes continue to ... and quality of life of patients, in ... complications are known to be associated with ... that the level of haemoglobin A1c (HbA1c) ...
Medicine Products: